Overview

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are: - Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment. - Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiatan Pharmatech Co., Ltd